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ABSTRACT
Introduction: The National Cancer Institute of Canada
(NCIC) Clinical Trials Group (CTG) Quality of Life (QOL)
Committee was initiated in 1986.
Purpose: The purpose of this review is to describe the evo-
lution of the Committee’s work and to highlight key devel-
opments such as the formulation of a policy regarding
health-related quality-of-life (HRQOL) assessment, the pro-
vision of guidelines to ensure completion of HRQOL data
within the protocol requirements, the rationale behind
the choice of HRQOL instruments, the timing of assess-
ments and the development of data analytic methods. These
developments are illustrated with examples from CTG
studies.
Recommendations: There is a lack of concordance between
conventional toxicity data and HRQOL data and compara-
tive studies designed to elucidate these differences are to be
encouraged. Also, more studies are required to compare dif-
ferent analytic strategies and to determine how much missing
data is acceptable, particularly in oncology studies where
attrition is inevitable.
Keywords: assessment, clinical trials, oncology, QOL, quality
of life.
The Quality of Life Committee—Description
The experience of the National Cancer Institute of
Canada (NCIC) Clinical Trials Group (CTG) in
health-related quality-of-life (HRQOL) assessment
began in 1986 with the formation of a Quality of Life
(QOL) working group. The role of the working group
was to provide educational opportunities to the CTG
clinical investigators and other CTG personnel. A
standing QOL Committee was established in 1987 [1].
Subsequently, HRQOL assessment in the CTG has
evolved gradually in keeping with developing world-
wide knowledge. In several ways, the CTG has been
instrumental in introducing new information during
this evolution. Some of these advances are detailed in
this article, which gives particular emphasis to how
our policy and procedures have led to useful methods
and results, and how this experience may be useful for
developing Food and Drug Administration guidance
for labeling claims.
Policy
The Committee developed a policy pertaining to
HRQOL assessment in the context of clinical trials [1].
The policy stated that “there should be a statement
about the anticipated impact on quality of life with
every proposed Phase III clinical trial and whether
QOL measures will be incorporated in the protocol.”
As a result of this policy, almost all of the 71 trials
initiated by the CTG since its adoption in 1987 include
HRQOL components. This provides the CTG with
extensive experience to determine which procedures
have worked best in given situations, and the results
have provided new information. Between 1992 and
2006, the QOL Committee published 45 full articles,
69 abstracts, and 6 miscellaneous publications. The
presence of a CTG policy, however, does not always
lead to the inclusion of HRQOL assessments in inter-
group trials if the lead group does not feel it necessary
to include such assessment.
Writing Guidelines
The QOL Committee provides writing guidelines for
the inclusion of HRQOL assessment in clinical trials
protocols [1,2]. HRQOL components should be a part
of the main protocol and not an add-on. Inclusion of
HRQOL components in the main protocol is desirable
because adding on separate protocols creates the
impression that HRQOL assessment is either not very
important or that it is an afterthought.
The writing guidelines provide explicit instructions
for the sections of the protocol dealing with the
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introduction, rationale and hypothesis, objectives of
HRQOL assessment, eligibility criteria, study design,
sample size, instrument description, instructions for
administration of the instruments, timing of assess-
ments [3], analysis, and wording of the consent form.
Instructions to Clinical Research Associates (CRAs)
At the outset, the QOL Committee developed instruc-
tions for the integration of HRQOL measurement into
Phase III clinical trials [1]. These instructions are used
by CRAs, ofﬁce data managers, and others who will be
involved in collecting the data. They include the ratio-
nale for the HRQOL component, how to present
HRQOL questionnaires to patients, how to collect
them after completion, and how to transmit the com-
pleted questionnaires to the central CTG ofﬁce. As a
result, all personnel involved with an HRQOL com-
ponent in a trial understand the need for measuring it
and the procedure for standardized collection of the
data. Because central ofﬁce staff who conduct the main
part of the clinical trial are the same individuals who
receive the HRQOL data, there is integration of all
components of the trial by one group of personnel. We
believe that this is an advantage over having separate
personnel dealing with the HRQOL component and
with the primary component of the trial (i.e., the
primary objective).
A particularly important instruction to the CRAs is
that they should obtain a completed HRQOL ques-
tionnaire on a patient before calling the central ofﬁce
for randomization instructions. This is intended to
make certain that questionnaire completion rates at
baseline are high. Nevertheless, if a patient is not able
to answer a questionnaire because of language barri-
ers, but meets all the other inclusion criteria, the
patient is not excluded from participation in the study.
Liaison with Disease Site Groups (DSGs)
TheQOLCommittee members provide liaison to DSGs
and educational resources to members of the CTG.
Members of the QOL Committee act as liaison
members between the QOL Committee and speciﬁc
DSGs so that the HRQOL component of a proposed
trial can be incorporated into the protocol at an early
stage of the planning process. In addition, feedback to
the DSGs on the success of collection of the HRQOL
data can be provided as the trial progresses. To ensure
that DSGs are well acquainted with the need to collect
QOLdata andwhat this entails, theQOL liaison person
is a member of the executive committee for each DSG.
Completion Rates of HRQOL Instruments (Compliance)
The above policy and procedural instructions are
intended to produce high questionnaire completion
rates so as to keep avoidable (random) missing data
to a minimum. Completion rates are determined as
follows: number of questionnaires received with sufﬁ-
cient items answered to be deemed complete [4]; the
number of questionnaires received over the number of
patients enrolled in the trial; and the number of ques-
tionnaires received over the number expected (number
of patients still on study and required to complete
questionnaires according to the protocol). To date,
almost all trials with HRQOL components have base-
line completion rates higher than 97% [5–7]. On-study
completion rates are lower, but the number completed
over the number that can be expected to be completed is
usuallymore than 80% (unpublished data) [5–7]. These
completion rates are among the best in the world, and
we believe that they are a consequence of the diligent
efforts of our CRAs and central ofﬁce personnel.
Choice of HRQOL Instruments
When the QOL Committee was formed, there were
only a small number of HRQOL instruments from
which to choose. Only two or three had been devel-
oped for use in patients with cancer. One of the
members of the QOL Committee became a liaison
member from the CTG to the European Organization
for Research and Treatment of Cancer (EORTC)
Quality of Life Study Group and was made aware of
the properties of the Quality of Life Questionnaire
(QLQ) being developed by that group [8]. The details
of the questionnaire’s reliability and validity were
reviewed by the CTG QOL Committee, and it was
decided to adopt the use of this questionnaire for CTG
purposes. The decision was made to use this question-
naire as our standard questionnaire in clinical trials for
a number of reasons. First, it provides separate domain
and single-item scores rather than a single aggregated
or summary score. Having separate scores allows a
detailed picture of how different domains of HRQOL
are affected by a disease and its treatment. Although
a single aggregated score is appealing because it is
simpler to deal with, it hides changes in HRQOL
domains that move in opposite directions or that may
differ according to the treatment a patient receives.
Second, using the same instrument in a variety of
disease sites allows us to become very familiar with its
properties and behavior in a variety of cancer popula-
tions. Third, it allows us to make comparisons across
clinical trials at different disease sites if we wish to do
so. Finally, the use of one questionnaire allows for
simplicity of administration at the clinic level and in
data management at the central ofﬁce. Eventually, we
began to use other questionnaires if we were partici-
pating in a trial initiated by another cooperative clini-
cal trials group or if it was felt that another instrument
had some properties that made it desirable for use in a
particular trial. We have used 24 different instruments,
but the EORTC QLQ-C30 (the core instrument with
30 items) has been used in 51 of 71 (71.8%) trials.
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Development of Study-Speciﬁc Checklists
Generic and general QOL instruments need to be
supplemented with disease-speciﬁc modules [9] or
with study-speciﬁc items to provide a more complete
collection of the necessary HRQOL data [10]. Al-
most no disease-speciﬁc modules/checklists existed
for use in cancer populations by the early 1990s. By
study-speciﬁc items, we refer to items that are speciﬁc
to a particular trial and that ask questions not
covered in the core questionnaire or a disease-speciﬁc
module. Examples include symptoms caused by the
disease or its treatment (e.g., difﬁculty passing urine
in prostate cancer, bleeding from the vagina, the
bladder, or rectum after radiation therapy (RT) for
cervical cancer or for prostate cancer, or fever after
treatment with interferon or from infection after
chemotherapy.) Study-speciﬁc checklists are supple-
mentary to disease-speciﬁc modules and general or
generic instruments. Because they consist of single
items, they cannot be tested for reliability or validity
in the usual ways, but they can be assessed for under-
standability and acceptability to the patient.
Several study-speciﬁc checklists were developed by
the QOL Committee. As an example, one of these has
been used in the MA.14 breast cancer trial of tamox-
ifen versus tamoxifen plus octreotide in postmeno-
pausal women with primary breast cancer who have
undergone deﬁnitive surgical management [11]. The
analysis of the MA.14 HRQOL checklist results shows
that, in the short term, the selective checklist item
scores discriminate between patients differing in clini-
cal status and are responsive to change over time as
well as to treatment-induced differences. The selective
checklist item scores correlate statistically signiﬁcantly
with the patient’s global QOL scores and provide addi-
tional information to that provided by the EORTC
QLQ-C30 core questionnaire and the EORTC breast
cancer module QLQ-BR23 (http://www.cancer.gov/
clinicaltrials/EORTC-15931).
Results
In this section, the results of several CTG studies are
presented to illustrate how HRQOL assessment helps
to better understand the effects of cancer and its treat-
ment on patients’ lives, to determine which treatment
produces better HRQOL in randomized trials, and to
provide recommendations that may help in the formu-
lation of a guidance document. Many of our ﬁndings
are based on large numbers of patients pooled
together, in some cases, from several trials. It was
possible to do this because of our early decision to use
the same instrument (the QLQ-C30) in most of our
trials. Had we used different instruments in each trial,
the numbers could not have been combined and would
have been too small to provide reliable data.
Validation and Reliability Studies
Further validation (reliability and validity) of the
QLQ-C30 was established in ovarian, breast, and lung
cancer [12]. In addition, CTG studies helped to modify
the original version of the QLQ-C30 into the second
and third versions of the questionnaire [13,14].
Nausea and Vomiting after Chemotherapy
Studies of chemotherapy-induced nausea and vomiting
in 832 chemotherapy-naive patients, enrolled in
studies of either highly or moderately emetogenic che-
motherapy, elucidated the deleterious effects of nausea
and vomiting together and of each independently on
physical, social, and cognitive functioning as well as on
fatigue, appetite loss, and global QOL [15,16]. A study
of risk factors associated with postchemotherapy
nausea and vomiting in these patients revealed that
low social functioning, prechemotherapy nausea,
being female, increased fatigue, and a lower perfor-
mance status were associated with a higher risk of
either vomiting or nausea after highly emetogenic che-
motherapy [17]. After moderately emetogenic chemo-
therapy, however, some prognostic factors seemed to
be inconsistent, and the probability of postchemo-
therapy nausea and vomiting was more strongly inﬂu-
enced by the type of chemotherapy given and the type
of antiemetic used rather than by patient or by envi-
ronmental factors [18].
It was also established in a study of moderately
emetogenic chemotherapy that patients could be relied
upon to pay attention to the time frame of the ques-
tions, because their answers were consistent with the
expectation that postchemotherapy nausea and vomit-
ing would have a greater impact on HRQOL during
the ﬁrst 3 days after chemotherapy than during the
subsequent 4 days [19]. Very short time frames (e.g.,
1 day) provide inconsistent data because the time
frame is too short, and therefore 3- to 7-day time
frames are recommended to provide the most reliable
data [20].
Fatigue
In 2390 patients with a variety of cancers, greater
fatigue severity was found to be associated with being
female, metastatic disease, and poorer performance
status. The oldest patients and patients with breast
cancer reported less fatigue, while patients with
ovarian cancer or lung cancer had greater fatigue [21].
Patients in antiemetic trials whose nausea and vomit-
ing were well controlled showed less fatigue than did
those with poor control of nausea and vomiting. Nev-
ertheless, patients who had complete control of nausea
and vomiting after highly emetogenic chemotherapy
still had greater fatigue than at baseline [16]. Thus, not
all postchemotherapy fatigue can be attributed to poor
S140 Osoba et al.
control of nausea and vomiting. These studies were
important in establishing the concept that complete
control of nausea and vomiting following chemo-
therapy is ideal [22].
Prognostic Factors for Survival and Treatment Effects
A study of prognostic factors for survival in a hetero-
geneous group of 474 patients who had either local-
ized or metastatic disease and who had been entered
into chemotherapy trials showed that lower global
QOL scores on the QLQ-C30 at baseline were inde-
pendently associated with shorter survival [23].
In other clinical trials, CTG studies have shown
that pretreatment global QOL scores were a predictor
of on-treatment global QOL in patients with malig-
nant melanoma [24]. In advanced ovarian cancer,
patients treated with cyclophoshamide and cisplatin
had less deleterious impact on HRQOL during treat-
ment than patients treated with paclitaxel and cispl-
atin. The latter patients reported more difﬁculty with
myalgia and neurosensory problems than did the
former, but by a year after treatment, both groups
were similar [25].
An intergroup trial between an Italian group and
the CTG in Stage II and IV nonsmall-cell lung cancer
(NSCLC) found that although patients treated with
gemcitabine plus vinorelbine reported fewer problems
with appetite, vomiting, alopecia, and ototoxicity
than patients receiving cisplatin-based chemotherapy,
their lung cancer symptoms were not as well con-
trolled and there was no overall difference in global
QOL between the cisplatin and non–cisplatin-based
chemotherapy [26]. QOL was the primary study end
point in that study, and provided clinically useful
information that was not previously known. A large
study of the targeted agent, erlotinib, versus placebo
as second- or third-line treatment for Stage IV
NSCLC revealed a clinically and statistically signiﬁ-
cantly longer median time to deterioration of pre-
deﬁned index symptoms for patients on the erlotinib
arm (e.g., 4.7 vs. 2.9 months for dyspnea) as well as
improvements in global QOL and physical function.
These ﬁndings conﬁrmed that the observed survival
beneﬁt is truly of clinical beneﬁt as it provides better
palliation and QOL [27].
Another study in extensive-stage small-cell lung
cancer, however, showed how HRQOL can be
adversely affected by a new, dose-intensive therapy as
compared with standard therapy [28]. This trial was
stopped before completion of accrual because of an
excess of early deaths, but the HRQOL data also
showed a clear worsening of physical functioning,
fatigue, and global QOL in the dose-intensive arm. A
randomized trial of preoperative versus postoperative
RT in 190 patients with extremity soft tissue sarco-
mas showed that those who received postoperative
RT had better limb function and less pain at 6
weeks after surgery than did patients with preopera-
tive RT [29]. There were no differences at later time
points. The conclusion was that timing of RT had a
minimal impact on function in the ﬁrst year after
surgery.
Observer Ratings versus Direct
Patient-Reported Outcomes
A study using 12 simulated patients asked seven expe-
rienced clinical data managers to score toxicity grades
using the NCIC CTG and the World Health Organi-
zation (WHO) toxicity scales [30]. Modest levels of
inter-rater reliability were demonstrated with kappa
values that ranged from 0.50 to 1.00 in laboratory-
based categories and from -0.04 to 0.82 for clinically
based categories. Proportions of agreement for clinical
categories ranged from 0.52 to 0.98. Condensing the
toxicity grades improved statistics of agreement, but
substantial lack of agreement remained (kappa range
-0.04 to 0.82; proportions of agreement range 0.67–
0.98). Thus, experienced data managers, when inter-
viewing patients, draw varying conclusions regarding
toxic effects experienced by such patients. Neither the
NCIC CTG-expanded toxicity scale nor the WHO
standard toxicity scale demonstrated a clear superior-
ity in reliability, although the breadth of toxic effects
recorded differed.
In addition, a low correlation exists between
patient-reported toxicity and toxicity grade by observ-
ers [31]. Between 1988 and 1990, the NCIC CTG
conducted a multicenter Phase III trial that compared
two immunomodulating agents as long-term adjuvant
therapy in resectable malignant melanoma [24]. Inci-
dence and severity data on 11 symptoms of particular
interest were collected by each of three methods: the
case report ﬂow sheet (FS) completed by study person-
nel, the Symptom Diary (SD), and the QLQ-C30 (the
latter two patient-reported). Both the FS and SD
included a preset list so that each toxicity required a
graded response (0 = none).
Ten of the 89 available cases were randomly
selected for an initial analysis. In four patients, all
three methods produced either identical or only
slightly differing records of the expected toxicities. In
ﬁve patients there were discrepancies. In one patient,
each method documented different toxicities. In four
cases, the QLQ-C30 picked up more symptoms than
the SD or FS. The SD in turn picked up more symp-
toms than did the FS. Finally, one case was not evalu-
able as treatment was stopped after 2 weeks, but the
QLQ-C30 was not done until 16 weeks. Preliminary
results thus indicate that reporting of treatment-related
symptoms can differ substantially among these three
methods of data collection.
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A more recent study involving 303 patients with
advanced breast cancer compared the level of agree-
ment between patients’ self-evaluations and health-
care personnel’s accounts of patients’ symptoms [32].
Fifteen “matched” symptoms from the QLQ-C30 and
the NCIC CTG-expanded Common Toxicity Criteria
were evaluated over seven common time points. Agree-
ment was only fair to slight (kappas from 0.012 to
0.378) between patients and health care personnel
and worsened over time. In general, patients reported
many more symptoms than did health care personnel.
Therefore, the use of only toxicity grading by health-
care personnel may result in under-reporting of toxic-
ity, thus altering study results. Further studies are
required to explain these discrepancies.
Analysis of HRQOL Data
The analysis and reporting of HRQOL data has under-
gone a gradual evolution. Initially, NCIC investigators
sought to determine whether there was a statistically
signiﬁcant difference in the means of domain mean
scores between the treatment arms of a study [24].
Those with higher scores may be healthier than those
with lower scores. Using only mean scores may result
in a possible survivor bias.
Subsequently, several studies have compared the
means of the changes in HRQOL scores from baseline
between treatment groups [16–18]. In this approach,
the change in a patient’s scores is calculated by sub-
tracting the baseline score from subsequent on-study
scores. Thus, only scores of patients who are still on
study are used. The advantage is that a spurious
increase in the group mean scores is eliminated because
an individual patient’s on-study scores are compared
only with that patient’s own baseline scores. The dis-
advantage, however, is that analysis of this subset of
patients may limit the generalizability of the results to
the whole sample. Also, when the individual differ-
ences are taken together, the mean change in scores
from baseline between groups does not inform us of
the clinical signiﬁcance of the change in scores. For
example, as alluded to earlier, is a difference of 5% in
the mean change scores clinically meaningful? Knowl-
edge of the change for the entire group also does not
inform us of the differences reported by individual
patients, some of whom may have experienced larger
changes in scores while others experienced smaller
changes.
Measuring Clinically Meaningful Change
Is a change of 3 or 5 points on a scale of 0–100
important from a clinical perspective? The CTG chose
to study this question by building on an approach
used to determine the minimal important difference
(MID) as suggested by the studies of a group at
McMaster University [33,34]. A Subjective Signiﬁ-
cance Questionnaire was used to determine the small-
est amount of change on four QLQ-C30 domains that
was perceptible to patients with advanced breast
cancer and small-cell lung cancer as a change from
the previous time that they had completed the QLQ-
C30. It was found that the smallest subjectively sig-
niﬁcant change perceptible to patients is between 5%
and 10% of the breadth of the QLQ-C30 for physi-
cal, social, and emotional functioning and global
QOL [35]. A change of 11% to 20% is moderate and
changes of more than 20% are large. On average,
these changes correspond to effect sizes of less
than 0.5, 0.5 to 0.8, and more than 0.8, respectively
[35].
Several other studies in patients with different
diseases, completing different questionnaires, have
shown that a change of about 7% to 8% of the scale
breadth is perceived as a change from baseline
[33–36]. By using other external anchors to deter-
mine a MID, a similar difference has been determined
[37,38]. The magnitude of this difference is about 0.4
of a standard deviation or of an effect size [39,40].
Thus, this difference can be used as a cut point
to distinguish patients who have experienced an
HRQOL beneﬁt from those who have not experi-
enced a beneﬁt. Using a cut point right at the MID,
however, may include “false positives” as having
experienced a true beneﬁt. Therefore, a higher cut
point (i.e., 10%) to distinguish those who have had
a true HRQOL beneﬁt from those who have not
is recommended [41–47]. A 10% cut point is about
0.5 of a standard deviation or of an effect size
[35,39,40]. In addition to being used for determining
the proportions of patients with an HQROL beneﬁt,
the cut point can also be used to compare the dura-
tion of beneﬁt within and between groups of patients.
Also, the magnitude of these changes can be helpful
for calculating sample sizes required to detect a speci-
ﬁed change in clinical trials.
NCIC CTG Recommendations for Analysis
The NCIC CTG recommends a relatively simple,
clinically practical analysis that consists of four steps
[47]. After calculation of the questionnaire completion
rates and the baseline scores, the individual change
scores from baseline are determined. Then, the propor-
tions of patients who have reported a predetermined
clinically signiﬁcant change score (usually more than
10%) are calculated, and the differences in the number
of patients who have beneﬁted in each treatment group
are tested for statistical signiﬁcance. An advantage of
this approach of calculating the proportion of patients
with an “HRQOL response” is that patients with
missing data may still be included in an intention-to-
treat analysis.
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A recent study compared the NCIC CTG QOL
standard protocol with two other methods, summary
measure and summary statistic-based approaches,
and linear mixed model-based methods, in analyzing
HRQOL data based from a randomized clinical trial
in patients with advanced breast cancer [48]. The dif-
ferent statistical approaches have both advantages
and disadvantages. The CTG standard protocol is
easy to implement and takes clinical importance into
account in the analysis of the QOL data. Other
summary measures and statistics-based approaches
are also simple to interpret. The time effects cannot
be assessed with these approaches. Model-based
methods take the correlation between repeated mea-
surements into account and could test the treatment
effect over time. For a comprehensive exploratory
analysis, model-based methods would seem to be
essential. The assumptions underlying the model-
based approaches, however, are difﬁcult to verify and
have a strong impact on the validity of the analysis
results.
This study did not identify a method that is better
than all other approaches, and our suggestion is that,
in the analysis of QOL data, different methods should
be explored to assess the robustness of the results.
Other analyses, such as growth curves [28,49] or
pattern mixture models [50,51], may be applied. An
additional useful analysis is to calculate the proportion
of patients reporting a “HRQOL response” within a
treatment group. This is useful not only in nonran-
domized Phase II trials, where there is no comparison
group [45], but also in Phase III randomized studies
[44,46].
Conclusions
The strategies for and the approach to assessing
HRQOL in clinical trials have evolved over time
within the CTG. Some of the strategies that were set
in place at the outset, such as developing a policy,
producing writing guidelines and explicit instructions
to CRAs and other personnel, and assigning liaison
members to DSGs, have proved useful over time.
These strategies have produced high questionnaire
completion rates with a minimum of randomly
missing data due to administrative error. A rationale
has been presented for our decision to use a single
questionnaire, the QLQ-C30, in most of our trials.
The QOL Committee of the CTG has produced
simple guidelines for the analysis of HRQOL data
that culminate in a determination of the proportions
of patients who beneﬁt from treatment. Whether our
simple response-based analysis is sufﬁciently robust
for most purposes is still uncertain, and it needs to be
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